[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,483,256
  • Shares Outstanding, K 247,782
  • Annual Sales, $ 2,320 M
  • Annual Income, $ 782,570 K
  • EBIT $ 972 M
  • EBITDA $ 1,001 M
  • 60-Month Beta 0.44
  • Price/Sales 5.48
  • Price/Cash Flow 16.96
  • Price/Book 6.90

Options Overview Details

View History
  • Implied Volatility 34.60% (-1.50%)
  • Historical Volatility 39.78%
  • IV Percentile 27%
  • IV Rank 17.79%
  • IV High 71.05% on 10/17/25
  • IV Low 26.71% on 08/28/25
  • Expected Move (DTE 8) 1.32 (2.60%)
  • Put/Call Vol Ratio 0.39
  • Today's Volume 444
  • Volume Avg (30-Day) 1,408
  • Put/Call OI Ratio 1.39
  • Today's Open Interest 52,577
  • Open Int (30-Day) 42,113
  • Expected Range 49.29 to 51.93

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.79
  • Number of Estimates 5
  • High Estimate $0.84
  • Low Estimate $0.71
  • Prior Year $0.67
  • Growth Rate Est. (year over year) +17.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.99 +1.24%
on 08/13/26
56.95 -11.13%
on 08/05/26
-5.43 (-9.69%)
since 07/13/26
3-Month
48.10 +5.21%
on 06/03/26
57.57 -12.09%
on 07/07/26
-0.68 (-1.33%)
since 05/13/26
52-Week
33.76 +49.93%
on 10/20/25
57.57 -12.09%
on 07/07/26
+12.12 (+31.49%)
since 08/13/25

Most Recent Stories

More News
EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL)

Exelixis shares fell after the Company reported Q2 revenue of approximately $628.7 million -- below Wall Street consensus -- and lowered its full-year 2026 revenue guidance, citing a slower-than-expected...

EXEL : 50.61 (+0.46%)
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis

Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigation...

EXEL : 50.61 (+0.46%)
Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL)

On May 5, 2026, Exelixis management reiterated full-year 2026 financial guidance. Weeks later, the Company lowered and narrowed that revenue outlook -- and the stock fell.

EXEL : 50.61 (+0.46%)
Exelixis: Q2 Earnings Snapshot

Exelixis: Q2 Earnings Snapshot

EXEL : 50.61 (+0.46%)
Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

- Total Revenues of $628.7 million, Cabozantinib Franchise U.S. Net Product Revenues of $573.0 million - - GAAP Diluted...

EXEL : 50.61 (+0.46%)
Can Exelixis Explain Why the Pipeline Matters More Than the Product Everyone's Waiting For?

Barchart Research What to Expect from EXEL Earnings EXEL Generated August 4, 2026 Current Price $56.01 EPS Estimate $$0.75 Consensus Rating Moderate Buy Average Move 9.99% Can Exelixis Explain Why the...

EXEL : 50.61 (+0.46%)
Exelixis: When Your Entire Valuation Rides on One Pipeline Readout

Barchart Research What to Expect from EXEL Earnings EXEL Generated July 24, 2026 Current Price $55.37 EPS Estimate $$0.75 Consensus Rating Moderate Buy Average Move 9.99% Exelixis: When Your Entire Valuation...

EXEL : 50.61 (+0.46%)
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT –

EXEL : 50.61 (+0.46%)
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver...

EXEL : 50.61 (+0.46%)
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –

EXEL : 50.61 (+0.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 52.39
2nd Resistance Point 51.95
1st Resistance Point 51.17
Last Price 50.61
1st Support Level 49.95
2nd Support Level 49.51
3rd Support Level 48.73

See More

52-Week High 57.57
Last Price 50.61
Fibonacci 61.8% 48.47
Fibonacci 50% 45.66
Fibonacci 38.2% 42.85
52-Week Low 33.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.